Abstract: The development of all-oral direct-acting antiviral agents (DAA) is a milestone in the history of hepatitis C treatment. In China, DDAs that have been approved or will be approved in the near future include daclatasvir, asunaprevir, sofosbuvir, ombitasvir/paritaprevir/ritonavir, dasabuvir and simeprevir. With high efficacy and good safety, these drug combinations make it possible to cure more Chinese patients with hepatitis C. The clinical trial data of the above-mentioned medicines were reviewed here, and the development goal of hepatitis C treatment and the prominent representatives of pan-genotypic combination of direct-acting antiviral agents were introduced, so as to provide reference for researches of hepatitis C and related drugs.